Skip to main content

GeneArt Nets Additional $800K in Expanded NCI Contract

NEW YORK (GenomeWeb News) – The National Cancer Institute has extended an existing agreement with synthetic genomics company GeneArt to produce genes for the NCI’s Mammalian Gene Collection, the company said today.
 
GeneArt said that it stands to gain an additional $800,000 from the expanded contract, bringing the total value of the agreement to $2.7 million in 2008.
 
The company said it netted $3.5 million in 2007 from the NCI contract, which was renewed earlier this year.
 
GeneArt said that the genes it has produced to date for the MGC are made of complex repeat motifs, are large, and are primarily rare transcripts. The company said it has recently advanced its synthesis processes and developed new production techniques to in order to produce the complex genes efficiently.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.